Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
The present study explored the impact of two novel criteria; having >95% abnormal plasma cells by flow cytometry at diagnosis and the evolving subtype of the disease, as predictors of progression in 61 smouldering multiple myeloma (SMM) and 311 monoclonal gammopathy of unknown significance (MGUS) patients. Although both criteria were of prognostic value, the risk of progression was better identified by immunophenotyping [Hazard Ratio (HR) 6.2 and 17.2 for SMM and MGUS, respectively] than evolving subtype, which had independent prognostic value only in MGUS (HR 3.6). Immunophenotyping discriminated the different risk of progression within the evolving and non-evolving subgroups of SMM (P = 0.01) and MGUS (P < 0.001).
Pérez-Persona
Ernesto
E
Department of Haematology, University Hospital.
Mateo
Gema
G
García-Sanz
Ramón
R
Mateos
María-Victoria
MV
de Las Heras
Natalia
N
de Coca
Alfonso García
AG
Hernández
José M
JM
Galende
Josefina
J
Martín-Nuñez
Guillermo
G
Bárez
Abelardo
A
Alonso
José M
JM
Martín
Alejandro
A
López-Berges
Consuelo
C
Orfao
Alberto
A
San Miguel
Jesús F
JF
Vidriales
María-Belén
MB
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018450:Disease Progression; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D016130:Immunophenotyping; D008297:Male; D008875:Middle Aged; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000276:immunology* / Q000473:pathology; D009101:Multiple Myeloma / Q000276:immunology* / Q000473:pathology; D010950:Plasma Cells / Q000276:immunology*; D011379:Prognosis